Shared Dysregulation of Homeostatic Brain-Body Pathways in Depression and Type 2 Diabetes
Purpose of Review
The purpose of this review is to provide an overview of shared dysregulation of the hypothalamic-pituitary-adrenal (HPA) and brain-gut-microbiome (BGM) axes associated with depression and type 2 diabetes (T2D). Clinical implications and future research are also discussed.
Both depression and T2D are associated with dysregulation of the HPA and BGM axes. These pathways regulate immune function, glucose metabolism, and sleep, which are altered in both illnesses. Dysregulation of homeostatic brain-body pathways may be positively influenced through different therapeutic actions, including psychotherapy, healthy eating, physical activity, sleep promotion, and certain anti-inflammatory or antidepressant medications.
While the causal nature of the relationship between depression and T2D remains unclear, these conditions share dysregulation of homeostatic brain-body pathways that are central to mental and physical health. Better understanding of this dysregulation may provide opportunities for interventions that could benefit both conditions. Future research should examine the additive burden of depression and T2D on HPA and BGM dysregulation and better differentiate depression from emotional distress.
KeywordsType 2 diabetes Depression Biological pathways Hypothalamic-pituitary-adrenal axis Brain-gut-microbiome axis
Dr. Gonzalez's effort is partialy supported by grants from the National Institutes of Health: R18 DK098742, R01 DK104845 and P30 DK111022. Support was also provided by The Drs. David and Jane Willner Bloomgarden Family Fellowship Fund.
Compliance with Ethical Standards
Conflict of Interest
Claire J. Hoogendoorn, Juan F. Roy, and Jeffrey S. Gonzalez declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.National Institutes of Mental Health. Major depression among adults. Available at: http://www.nimh.nih.gov/health/statistics/prevalence/major-depression-among-adults.shtml. Accessed 3/17 2017.
- 8.Nouwen A, Nefs G, Caramlau I, Connock M, Winkley K, Lloyd CE, et al. Prevalence of depression in individuals with impaired glucose metabolism or undiagnosed diabetes: a systematic review and meta-analysis of the European depression in diabetes (EDID) research consortium. Diabetes Care. 2011;34(3):752–62.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.• Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas M. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 8(1):2016, 42. This review provides a thorough overview of current knowledge regarding the mechanistic interactions between the gut microbiota, and host energy metabolism and immune system, as it relates to obesity and metabolic disease Google Scholar
- 47.Magouliotis DE, Tasiopoulou VS, Sioka E, Chatedaki C, Zacharoulis D. Impact of bariatric surgery on metabolic and gut microbiota profile: a systematic review and meta-analysis. Obes Surg. 2017:1–13.Google Scholar
- 67.• Snoek FJ, Bremmer MA, Hermanns N. Constructs of depression and distress in diabetes: time for an appraisal. Lancet Diabetes Endocrinol. 2015;3(6):450–60. This review describes evidence that diabetes distress and depression are distinct overlapping constructs, and reviews evidence that diabetes distress may mediate the relationship between depression and glycemic control. Further, the review outlines three distinct data-driven depression symptom profiles that appear to show differential relationships with metabolic outcomes CrossRefPubMedGoogle Scholar
- 72.Trinder M, Bisanz JE, Burton JP, Reid G. Bacteria need “sleep” too?: microbiome circadian rhythmicity, metabolic disease, and beyond. Univ Tor Med J. 2015;92(3)Google Scholar
- 74.American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub; 2013.Google Scholar
- 78.• Reutrakul S, Van Cauter E. Interactions between sleep, circadian function, and glucose metabolism: implications for risk and severity of diabetes. Ann N Y Acad Sci. 2014;1311(1):151–73. This review provides an update on current evidence from experimental, prospective and interventional studies linking sleep disturbance, circadian dysregulation, and glucose metabolism CrossRefPubMedGoogle Scholar
- 86.Manber R, Bernert RA, Suh S, Nowakowski S, Siebern AT, Ong JC. CBT for insomnia in patients with high and low depressive symptom severity: adherence and clinical outcomes. J Clin Sleep Med. 2011;7(6):645.Google Scholar
- 87.De Groot M, Doyle T, Kushnick M, Shubrook J, Merrill J, Rabideau E, et al. Can lifestyle interventions do more than reduce diabetes risk? Treating depression in adults with type 2 diabetes with exercise and cognitive behavioral therapy. Curr Diab Rep. 2012;12(2):157–66.CrossRefPubMedPubMedCentralGoogle Scholar
- 89.Laake JP, Stahl D, Amiel SA, Petrak F, Sherwood RA, Pickup JC, et al. The association between depressive symptoms and systemic inflammation in people with type 2 diabetes: findings from the South London Diabetes Study. Diabetes Care. 2014;37(8):2186–92.Google Scholar
- 90.Dinan TG. Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. Life Sci. 1996;58(20):1683–94.Google Scholar
- 100.Hiller-Sturmhöfel S, Bartke A. The endocrine system: an overview. Alcohol Res Health. 1998;22(3):153.Google Scholar